Controversy surrounds whether metformin's antitumorigenic benefits stems from its indirect effects via decreasing circulating insulin and glucose levels or its direct effects in tumor cells via AMPK activation and inhibition of the mTOR pathway. The gene discussed is MTOR; the disease is neoplasm.